Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 6/20 | 0.52 |
| ▸ | CDC25B | P30305 | 3/20 | 0.52 |
| ▸ | TDP2 | O95551 | 3/20 | 0.42 |
| ▸ | NSD2 | O96028 | 3/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.38 |
| ▸ | PADI1 | Q9ULC6 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065716 | 0.71 | S100A4 (0.45) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL71857 | 0.70 | — | — | |
| SCHEMBL223037 | 0.68 | CDC25B (0.50) | S100A4CDC25BTDP2TDP1MEN1 | |
| SCHEMBL31747733 | 0.68 | S100A4 (0.63) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL29747118 | 0.68 | S100A4 (1.00) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL25254110 | 0.68 | CDC25B (0.50) | S100A4CDC25BTDP2TDP1MEN1 | |
| SCHEMBL1507074 | 0.68 | S100A4 (1.00) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL6212776 | 0.68 | S100A4 (0.63) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL4262434 | 0.68 | CYP1A2 (0.38) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL2917444 | 0.68 | S100A4 (0.52) | S100A4CDC25BTDP2NSD2PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203496-A1 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-07-23 | — | — | US | claimed |
| US-20150111914-A1 | SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | claimed |
| US-20150087641-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-03-26 | — | — | US | claimed |
| EP-2846799-A1 | SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2846800-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2846798-A2 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2340025-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | claimed |
| US-8765759-B2 | Monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | claimed |
| EP-2339919-B1 | BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-12 | — | — | EP | claimed |
| EP-2271346-B1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-01 | — | — | EP | claimed |
| US-7189722-B2 | Aryl spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-13 | — | — | US | claimed |
| JP-2006520388-A | — | — | 2006-09-07 | — | — | JP | claimed |
| JP-2006520381-A | — | — | 2006-09-07 | — | — | JP | claimed |
| US-20060189593-A1 | Aryl spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-08-24 | — | — | US | claimed |
| WO-2006031606-A2 | CARBOXAMIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | claimed |
| WO-2006031513-A2 | ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | claimed |
| EP-1613368-A2 | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1605936-A1 | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004082678-A1 | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004082602-A2 | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203496-A1 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, OPRL1 | S100A4 2677/4885CDC25B 3723/4885TDP2 3224/4885 |
| US-20150111914-A1 | SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, TACR1 | S100A4 1914/4885CDC25B 3444/4885TDP2 2472/4885 |
| US-20060189593-A1 | Aryl spirohydantoin cgrp receptor antagonists | CALCRL, BDKRB2, MRGPRX1 | S100A4 2299/4885CDC25B 4578/4885TDP2 2705/4885 |
| US-20150087641-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | CCKBR, CALCRL, BDKRB2 | S100A4 1672/4885CDC25B 4231/4885TDP2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.